IGF-1 LR3 for Health & Longevity

Evidence Review created on 10/05/2026 using AI4L / Opus 5.5

Also known as: Long R3 IGF-1, LR3-IGF-1, LR3IGF-I, Long Arg3 IGF-1, IGF1-LR3, Long R3 Insulin-Like Growth Factor-1, LONG R3IGF-I

Motivation

IGF-1 LR3 (long R3 insulin-like growth factor 1) is a laboratory-made version of a natural growth signal the body releases in response to growth hormone. Two structural changes — one swapped building block and a short added tail — stop carrier proteins in the blood from capturing it, so more of an injected dose stays free to act on cells.

It was created in the early 1990s as a research tool for studying those carrier proteins, and it became an industrial ingredient in the nutrient broths used to grow cells in laboratories rather than a medicine. It is now sold as a research chemical and used outside medical supervision in bodybuilding and in some longevity-oriented practices, which is what brings it into the health and longevity conversation.

This review examines what the published literature does and does not establish for this molecule in adults: how it is thought to act, which effects have been measured and in which species, which harms have been documented, how it is regulated, and what can be tracked during use. Throughout, findings obtained with this engineered version are kept separate from findings obtained with the natural hormone or with the approved injectable form of it.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

High-level overviews of IGF-1 LR3 and of the growth-hormone/IGF-1 signalling axis it targets.

• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration - Dominikowski et al., 2026

  The only peer-reviewed clinical review that addresses IGF-1 LR3 by name, placing it in the lowest evidence tier and setting out how clinicians should interpret exposure to it.

• Meta-Analysis Discovers Goldilocks Zone for IGF-1 - Greg Gillispie

  Explains the pooled human evidence that both low and high circulating IGF-1 — the signal IGF-1 LR3 mimics at its receptor — carry higher mortality, and where the minimum sits.

• Benefits & Risks of Peptide Therapeutics for Physical & Mental Health - Andrew Huberman

  Explains how growth hormone drives IGF-1 and what sustained activation of that axis risks — the same axis IGF-1 LR3 enters directly at the IGF-1 receptor — and reviews the peptides aimed at it.

• Does increasing IGF-1 lead to cancer? – Rich Roll - Rhonda Patrick

  A freely available clip weighing how raising IGF-1 — the receptor signal IGF-1 LR3 activates — bears on cancer risk, and how dietary protein drives that same signal.

• #387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field - Peter Attia

  Freely readable show notes building a framework for grading grey-market peptides, including those driving the growth-hormone/IGF-1 axis that IGF-1 LR3 enters at the IGF-1 receptor.

Only five items qualify. Content from two other priority sources could not be used: Life Extension’s IGF-1 coverage always sits inside an article about something else — a 1998 prostate-cancer commentary, a 2009 feature on boosting growth hormone with nutrients, a 2016 feature on centenarian genetics and metformin with one section on low IGF-1 and longevity — never the receptor signal itself; and Chris Kresser treats the IGF-1 pathway only in passing inside broader nutrition and ageing articles.

Grokipedia

• IGF-1 LR3

  Covers the structural modifications, the engineering history and the doping classification, and states plainly that no peer-reviewed human study confirms muscle effects in healthy adults.

Examine

No Examine article exists for IGF-1 LR3. The site’s only related page treats IGF-1 as a biomarker that supplements may shift, not this engineered analogue, and Examine does not cover unapproved injectable research peptides.

ConsumerLab

No ConsumerLab article exists for IGF-1 LR3. ConsumerLab tests retail supplements, so an injectable research peptide that is not sold as a supplement falls outside its testing programme.

Systematic Reviews

No systematic reviews or meta-analyses for IGF-1 LR3 were found on PubMed as of 02 October 2026.

Both sides of this intervention’s central trade-off are therefore unrepresented at systematic-review level: neither the claimed muscle-building benefit nor the principal risk of sustained IGF-1 receptor activation has been pooled for this compound.

Mechanism of Action

IGF-1 LR3 is an 83-amino-acid analogue of insulin-like growth factor 1: arginine replaces glutamate at position 3 and a 13-residue extension is fused to its starting end (N-terminus). Both cut binding to the IGF binding proteins (IGFBPs, carrier proteins that hold roughly 99% of circulating IGF-1 inactive). Affinity for IGFBP-3 falls about 1,000-fold, while receptor affinity is roughly threefold lower than native IGF-1 (Francis et al., 1992; Ballard et al., 1993) — both from the Adelaide group that developed and commercialised the compound. Potency comes from a larger free fraction — the analogue beats native IGF-1 in cells secreting IGFBPs and is weaker in cells that do not (Francis et al., 1992).

At the receptor the signal runs through insulin receptor substrate 1 into the PI3K/Akt/mTOR pathway (a nutrient- and growth-sensing cascade that drives protein synthesis), and suppresses the FoxO proteins that switch on protein breakdown (Dominikowski et al., 2026). Weak insulin-receptor cross-activation explains the glucose-lowering effect.

A competing reading matters. Escaping the carrier proteins also removes the reservoir that prolongs IGF-1’s residence in blood: in rats the analogue is cleared about ten times faster than native IGF-1 (metabolic clearance 9.8 versus 0.9 mL/min/kg), and it distributes preferentially to kidney, ovary and adrenal rather than liver or brain (Bastian et al., 1993). No human pharmacokinetic study (how the body handles drugs) exists; elimination is by protein breakdown and kidneys, not liver enzymes. The widely repeated 20–30 hour half-life has no peer-reviewed human source (Dominikowski et al., 2026).

Historical Context & Evolution

IGF-1 LR3 was not designed as a therapy. It emerged from the Cooperative Research Centre for Tissue Growth and Repair in Adelaide in 1992 as one of a family of N-terminally modified IGF-1 fusion peptides built in Escherichia coli, whose purpose was to separate the contribution of receptor binding from the contribution of carrier-protein binding to biological potency (Francis et al., 1992). The hydrophobic extension also improved folding and yield, making production cheap.

Through the 1990s the same group used it as a probe: in dexamethasone-treated rats it partly reversed steroid-induced wasting about 2.5-fold more potently than native IGF-1 (Tomas et al., 1992), and gut, kidney and bowel-resection models showed where carrier proteins gate IGF-1 delivery (Steeb et al., 1994; Martin et al., 1994; Lemmey et al., 1994). Those findings were read as a case for IGFBP-sparing analogues in tissue-wasting illness. That development never happened in humans; instead the molecule found a commercial niche as LONG R3IGF-I, an animal-component-free insulin substitute in industrial cell culture, commercialised by GroPep and distributed by SAFC Biosciences — a supplier interest in the compound that predates any human claim.

Human-use interest arrived from a different direction. Doping-control chemists documented the analogue in a confiscated injection vial in 2010, in a histidine-tagged form (carrying a short purification label) made for biochemical research (Kohler et al., 2010). Opinion has since bifurcated: the research literature still treats it as a reagent, while an unregulated market treats it as a muscle-builder. Neither position rests on human outcome data.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: not one human outcome trial of IGF-1 LR3 has been conducted, so there is no clinical endpoint for this compound that independent research groups could replicate — the human evidence below comes from trials of native recombinant human IGF-1 (rhIGF-1), a different compound.

Medium 🟩 🟩

No benefit reaches Medium: there is no single human trial of IGF-1 LR3 and no observational cohort with a comparison group that measured it; the available human cohort data measure the body’s own IGF-1 concentrations instead.

Low 🟩

Blood-Sugar Control ⚠️ Conflicted

Recombinant IGF-1 lowers glucose at insulin receptors; a randomised trial improved blood sugar in type 1 diabetes (Thrailkill et al., 1999), while a 12-month randomised trial left post-meal glucose disposal unchanged in healthy older women (Friedlander et al., 2001). Indirect — a different compound. Net: benefit confined to diabetes.

Magnitude: 0.5 percentage points greater fall in HbA1c (glycated haemoglobin, a measure of average blood sugar over roughly three months) than optimised insulin alone over 12 weeks — 1.2% versus 0.7%, 223 participants randomised (Thrailkill et al., 1999); the 12-month randomised trial in healthy older women found no between-group difference in post-meal glucose disposal (Friedlander et al., 2001).

Body-Fat Reduction ⚠️ Conflicted

Recombinant IGF-1 shifts fuel use. In an uncontrolled type 2 diabetes series, body fat fell 2.1% without weight change (Moses et al., 1996); a randomised 12-month trial in healthy older women showed nothing (Friedlander et al., 2001). Indirect — a different compound. Net: effects appear only where metabolism is impaired.

Magnitude: 2.1% absolute reduction in body fat on dual-energy X-ray absorptiometry (a scan that measures fat, muscle and bone separately) over six weeks in 12 patients with type 2 diabetes — no control group (Moses et al., 1996). The randomised 12-month trial reported no difference from placebo in lean mass, fat mass or percent body fat (Friedlander et al., 2001).

Muscle Strength and Bone Recovery After Fracture ⚠️ Conflicted

After hip fracture, an IGF-1/carrier-protein complex showed favourable grip-strength and hip-density trends versus placebo (Boonen et al., 2002); a year of native rhIGF-1 changed neither in healthy older women (Friedlander et al., 2001). Indirect — different compounds, one carrier-bound. Net: any effect appears confined to post-injury recovery.

Magnitude: Grip strength rose 11.4% from baseline on the higher dose (p = 0.04; a p-value is the probability of a result this large arising by chance alone) while the placebo group lost 11.6% (p = 0.16), and hip bone density fell 2.6% versus 6.1% with placebo — not compared between groups, 30 participants (Boonen et al., 2002); the 12-month randomised trial found no difference from placebo in grip, bench-press or leg-press strength or in hip bone density (Friedlander et al., 2001).

Slower Functional Decline in Motor Neuron Disease ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Bears only on a neurological disease’s progression, not longevity. A Cochrane meta-analysis of native rhIGF-1 found slower decline on a rating scale in two randomised trials; a larger third trial was null and survival unchanged (Beauverd et al., 2012). Indirect — a different compound. Net: a weak signal from low-quality trials.

Magnitude: 4.75 points less decline on a disease rating scale than placebo at nine months (95% CI 1.09–8.41; CI = confidence interval, the range in which the true value probably lies), pooled from two randomised trials of native rhIGF-1 with 449 participants; a third trial of 330 participants found no difference on muscle strength testing, and no trial showed a survival benefit (Beauverd et al., 2012).

Speculative 🟨

Muscle Protein Retention

In rats, IGF-1 LR3 outperformed native IGF-1 in retaining body protein (Tomas et al., 1992); in cattle it tended to spare muscle protein, with no native comparator (Hill et al., 1999). No human study exists.

Gastrointestinal Mucosal Growth

In normal rats, IGF-1 LR3 enlarged gut tissue more potently than native IGF-1; after bowel resection it reduced malabsorption, though with less potency advantage (Steeb et al., 1994; Lemmey et al., 1994). Animal data only.

Atherosclerotic Plaque Stabilisation

In mice, IGF-1 LR3 shifted vascular smooth-muscle cells toward a stable, plaque-strengthening cell type and reduced plaque instability (von der Thüsen et al., 2011). Mechanistic animal work only; no human vascular outcome has been measured.

Amyloid Plaque Remodelling

Seven months of intranasal IGF-1 LR3 remodelled amyloid plaques in Alzheimer-model mice but preserved neither behaviour nor memory (Engel et al., 2025). Animal only, and the cognitive endpoint failed outright.

Peripheral Nerve Regeneration

In rats with a severed sciatic nerve, a conduit releasing IGF-1 LR3 improved nerve regrowth comparably to a nerve graft (Yavuz et al., 2025). Animal and device data only.

Benefit-Modifying Factors

• Baseline IGF-1 and growth-hormone status: Response in the native-hormone literature concentrated in people whose own axis was impaired or whose insulin resistance was marked; adults with age-normal IGF-1 showed nothing over a year (Friedlander et al., 2001).

• Carrier-protein profile: The analogue’s whole advantage is IGFBP evasion, so it should shrink wherever IGFBPs are already low — in pregnant rats, whose IGFBPs fall, native IGF-1 was cleared about three times faster, moving toward the analogue’s rate (Bastian et al., 1993).

• Genetic polymorphisms: Variants altering receptor signalling plausibly shift response — a growth-hormone receptor variant missing one gene segment and length variants in the IGF1 gene’s on-switch region are candidates — but no pharmacogenetic study (gene variants versus drug response) of this analogue exists.

• Pre-existing conditions: In rats in a steroid-induced catabolic (tissue-breakdown) state the analogue was about 2.5-fold more potent than native IGF-1 (Tomas et al., 1992), but after kidney injury it showed no potency gain and worsened kidney function (Martin et al., 1994).

• Sex: Female mice with reduced IGF-1 receptor signalling lived 33% longer, against a non-significant 16% in males (Holzenberger et al., 2003); among nonagenarians, low IGF-1 predicted longer survival in women but not men (Milman et al., 2014).

• Age: Benefit framing weakens with age. IGF-1 falls across life, yet pooled cohorts place the lowest mortality mid-range; in studies of people over 70 the pattern was similar but weaker and borderline (Rahmani et al., 2022), so restoring youthful concentrations is not an established benefit.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: every documented human adverse event comes from trials and registries of native recombinant human IGF-1 or from animal studies of this analogue, so there is no human adverse-event finding for IGF-1 LR3 that independent groups could replicate.

Medium 🟥 🟥

No risk reaches Medium: no single human trial and no controlled observational study has measured any adverse outcome of IGF-1 LR3; every human adverse-event dataset cited below used a different compound.

Low 🟥

Hypoglycaemia ⚠️ Conflicted

IGF-1 LR3 lowered glucose longer than native IGF-1 in pigs (Tomas et al., 1997). Randomised native-hormone trials found hypoglycaemia (low blood sugar) no more frequent than comparators (Thrailkill et al., 1999; Acerini et al., 1997). Indirect — different compound. Net: plausible via insulin-receptor action, but not excess in controlled trials.

Magnitude: 49% of 76 children treated with native rhIGF-1 for up to 12 years reported hypoglycaemia — no control group, and events also occurred before treatment started (Chernausek et al., 2007); in a 306-patient manufacturer-sponsored surveillance registry the rate was 0.11 events per patient-year, of which 0.01 were serious, with no control group (Bang et al., 2023); in the 223-participant randomised trial, hypoglycaemia incidence was similar to insulin alone, with no per-group rate reported in the abstract (Thrailkill et al., 1999).

Fluid Retention, Swelling and Jaw Pain

Raising IGF-1 increases capillary leakiness: a crossover study showed greater dye diffusion in skin and retina on the native hormone (Hussain et al., 1995). In a randomised trial, higher doses produced unacceptable oedema (tissue swelling from fluid) and jaw pain (Thrailkill et al., 1999). Indirect — a different compound.

Magnitude: Direction only — oedema and jaw pain were dose-limiting at the two higher rhIGF-1 doses and not at the lowest, across 223 randomised participants; the trial reports no per-group event rate for these effects (Thrailkill et al., 1999).

Headache and Muscle or Joint Pain

Headache was the second most frequent adverse event in the approved native hormone’s registry, which also tracks muscle pain (Bang et al., 2021). A clinical review found muscle and joint pain documented only for tesamorelin among self-administered growth-axis peptides, not IGF-1 LR3 (Dominikowski et al., 2026). Indirect — different compounds.

Magnitude: Headache was the second most frequently reported adverse event during treatment (n = 41) among 242 children on native rhIGF-1 in the manufacturer’s registry — no control group (Bang et al., 2021); the review gives no rate for muscle or joint pain and reports no data for IGF-1 LR3 (Dominikowski et al., 2026).

Worsening of Existing Retinopathy ⚠️ Conflicted

Early worsening of retinopathy (damage to the light-sensing layer at the back of the eye) appeared at higher doses of the native hormone — a different compound (Thrailkill et al., 1999) — while a 24-week randomised trial found none (Acerini et al., 1997). Net: a dose-dependent signal confined to diabetes.

Magnitude: Direction only — early retinopathy worsening clustered at the two higher doses among 223 randomised participants, with no per-group rate published (Thrailkill et al., 1999); the 53-participant trial reported no change on retinal photographs in either arm (Acerini et al., 1997).

Injection-Site Reactions and Lipohypertrophy

Repeated subcutaneous dosing causes local fat thickening (lipohypertrophy) and inflammation. Pooled native-hormone trials found more injection-site reactions than placebo (Beauverd et al., 2012), and a long-term paediatric series reported frequent lipohypertrophy (Chernausek et al., 2007). Indirect — a different compound; non-sterile grey-market vials add infection risk.

Magnitude: Risk ratio (how many times more often the event occurred) 1.26 for injection-site reactions versus placebo (95% CI 1.04–1.54) across randomised trials of native rhIGF-1 in 779 participants, with no absolute event rates reported (Beauverd et al., 2012). Lipohypertrophy affected 32% of 76 treated children — no control group (Chernausek et al., 2007).

Lymphoid Tissue Overgrowth

IGF-1 receptor signalling drives tonsil and adenoid growth; tonsillar or adenoidal hypertrophy (enlargement) was common on the approved native hormone and is a labelled warning (Chernausek et al., 2007; INCRELEX prescribing information). Indirect — different compound, and a paediatric population.

Magnitude: 22% of 76 children treated for up to 12 years — no control group (Chernausek et al., 2007).

Acromegaly-Like Soft-Tissue and Organ Changes

IGF-1 receptor activation thickens soft tissue, as in acromegaly (growth-hormone excess enlarging face and hands). Coarsened facial features and fat gain are common adverse effects of the approved native hormone (Rosenbloom, 2009); its trials also recorded symptomless cardiomegaly (an enlarged heart) (INCRELEX prescribing information). Indirect — different compound, paediatric data.

Magnitude: Not quantified in available studies. The label reports these changes in unspecified numbers of treated children with no control group, and the review gives no incidence figure (Rosenbloom, 2009).

Raised Pressure Inside the Skull

Native rhIGF-1 can cause reversible intracranial hypertension (raised pressure around the brain), which is why the label recommends funduscopic (back-of-the-eye) examination (INCRELEX prescribing information); registries track it as a targeted event (Bang et al., 2021). Indirect — different compound, paediatric data.

Magnitude: Intracranial hypertension occurred in 3 of 71 children across the approved native hormone’s clinical studies — no control group — two resolving without interruption and the third after stopping, with treatment resumed at a lower dose; the registry entries that track it carry no denominator (INCRELEX prescribing information; Bang et al., 2021).

Allergic Reactions Including Anaphylaxis

Allergic reactions, including life-threatening anaphylaxis (a sudden whole-body allergic reaction), have been reported with the approved native hormone and are a labelled warning (Torjusen et al., 2008; INCRELEX prescribing information). Evidence is case reports and postmarketing data, indirect by compound.

Magnitude: The approved native hormone’s label estimates the frequency of postmarketing cases indicative of anaphylaxis at 0.3%, with no control group (INCRELEX prescribing information); the remaining evidence is single-patient case reports without denominators (Torjusen et al., 2008; Metz et al., 2009).

Cancer Risk From Sustained Receptor Activation ⚠️ Conflicted

IGF-1 receptor activation drives proliferation. Higher endogenous IGF-1 tracks higher prostate, breast, colorectal and thyroid cancer risk (Renehan et al., 2004; Knuppel et al., 2020), yet the same analysis found lower liver and ovarian risk. Indirect — the body’s own levels, not this analogue. Net: a credible but unproven hazard.

Magnitude: Odds ratio 1.49 for prostate cancer (95% CI 1.14–1.95; odds ratio = how much the odds of an outcome differ between compared groups) and 1.65 for premenopausal breast cancer (1.26–2.08), comparing the 75th with the 25th percentile of endogenous IGF-1 across 3,609 cases and 7,137 controls (Renehan et al., 2004); hazard ratio 1.08 per 5 nmol/L for colorectal cancer (1.03–1.13; hazard ratio = relative rate of events over time) among 394,388 participants, alongside reduced ovarian and liver cancer risk (Knuppel et al., 2020). Neither source reports absolute rates. Malignancies in pediatric patients on the approved native hormone are postmarketing reports without rates (INCRELEX prescribing information).

Speculative 🟨

Impaired Kidney Recovery After Ischaemia

In rats recovering from kidney ischaemia (loss of blood flow), IGF-1 LR3 lowered filtration more than an inactive control infusion and increased calcium deposits in kidney tubules (Martin et al., 1994). Animal data only.

Blunted Insulin Secretion

A week-long IGF-1 LR3 infusion into fetal sheep reduced insulin secretion through a defect in the insulin-producing islet cells (White et al., 2021); an acute infusion blunted it transiently (White et al., 2023). Animal only.

Suppression of the Body’s Own IGF Signalling

IGF-1 LR3 infusion lowered native IGF-1 and IGF-2 (a sister growth factor) in guinea pigs and cattle (Conlon et al., 1995; Hill et al., 1999), raising a rebound concern. Animal only.

Mislabelled or Contaminated Product

A black-market vial sold as this peptide contained a histidine-tagged research-grade variant whose effects in people are undescribed (Kohler et al., 2010). One product analysis; no human exposure outcome measured.

Risk-Modifying Factors

• Baseline glucose handling: Prior hypoglycaemia and a diagnosis of extreme growth-hormone resistance both predicted hypoglycaemia on the native hormone, so an impaired ability to correct falling glucose is the dominant modifier (Bang et al., 2023).

• Existing retinopathy: IGF-1 raised retinal capillary permeability even in healthy volunteers (Hussain et al., 1995), and early retinopathy worsening at higher doses was seen in people with diabetes (Thrailkill et al., 1999).

• Personal or family cancer history: Prior malignancy, premalignant lesions (changes that can become cancer) or strong family history amplify the cell-growth (mitogenic) concern (Dominikowski et al., 2026); malignancy is a label contraindication (INCRELEX prescribing information).

• Genetic polymorphisms: No variant has been shown to modify adverse response to this analogue. Candidates are inferred from pathway biology — growth-hormone receptor and IGF1 receptor variants — and remain theoretical.

• Sex: Human cancer-risk associations with IGF-1 differ by site and sex, with premenopausal breast cancer carrying the largest reported association (Renehan et al., 2004); no sex-specific adverse-event data exist for the analogue.

• Age: Older adults carry more undiagnosed malignancy and more vascular disease, and pooled cohorts place the lowest mortality mid-range rather than high (Rahmani et al., 2022), so the risk/benefit tilt worsens with age.

Key Interactions & Contraindications

• Insulin and insulin secretagogues (drugs that push the pancreas to release insulin — sulfonylureas such as glipizide, glimepiride; meglitinides such as repaglinide): Additive glucose lowering; severe hypoglycaemia. Severity: monitor (theoretical); mitigation: antidiabetic dose reduction. Native rhIGF-1 cotherapy cut insulin requirement 11–19% (Thrailkill et al., 1999).

• Growth hormone and growth-hormone secretagogues (tesamorelin, ipamorelin, ibutamoren): Compounding activation of the same axis; added fluid retention, unstable blood sugar and growth-signal exposure. Severity: avoid (theoretical) — no human study has combined them (Dominikowski et al., 2026).

• Anabolic-androgenic steroids (synthetic testosterone-like muscle-building drugs such as nandrolone, trenbolone): Frequent real-world co-exposure; overlapping effects on oedema, glucose dysregulation and soft-tissue symptoms, making attribution unreliable. Severity: caution (theoretical) (Dominikowski et al., 2026).

• Corticosteroids (anti-inflammatory steroid drugs such as prednisone, dexamethasone): Oppose IGF-1 action and raise carrier-protein concentrations, blunting effect; animal work showed the analogue partly reversing steroid-induced wasting (Tomas et al., 1992). Severity: caution (theoretical); consequence: reduced efficacy.

• Over-the-counter agents: No documented interaction. Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) may add to fluid retention, and high-dose aspirin lowers glucose itself, adding to hypoglycaemia. Severity: caution (theoretical).

• Supplement interactions with additive glucose lowering: Berberine, chromium, alpha-lipoic acid, bitter melon and cinnamon extract all lower glucose and can deepen hypoglycaemia. Severity: monitor (theoretical).

• Supplements and foods that raise endogenous IGF-1: Dairy products and high protein intake are associated with higher IGF-1 (Rahmani et al., 2022); amino-acid secretagogues (arginine, ornithine) may add to pathway activation. Severity: caution (theoretical).

• Other interventions: Resistance training activates this pathway and fasting suppresses it, so timing confounds any self-assessment of effect; exercise around a dose also deepens glucose lowering. Severity: caution (theoretical); consequence: hypoglycaemia and misattributed effect.

Populations who should avoid IGF-1 LR3:

• Anyone with active or previously treated malignancy, or a history of malignancy — an absolute contraindication on the approved native hormone’s label (INCRELEX prescribing information)
• Anyone with closed epiphyses (fused growth plates) seeking growth promotion — also a labelled contraindication, which covers all adults (INCRELEX prescribing information)
• People with existing diabetic retinopathy, where the dose-dependent eye signal was seen (Thrailkill et al., 1999)
• People with a documented history of hypoglycaemia, the strongest predictor of recurrence on the native hormone (Bang et al., 2023)
• Pregnant and breastfeeding women — no data exist; the label notes pregnancy exposure is unlikely only because the product is not used after growth-plate closure (INCRELEX prescribing information)
• Athletes in tested sport, for whom IGF-1 and its analogues are prohibited at all times by the World Anti-Doping Agency under category S2.3 (WADA Prohibited List)

Risk Mitigation Strategies

Parameters below follow common practice unless cited.

• Meal-anchored dosing against hypoglycaemia: Fast-acting carbohydrate kept at hand and a meal within about 20 minutes of each dose limit low-blood-sugar risk — the interval the approved native hormone’s label specifies to blunt its insulin-like effect (INCRELEX prescribing information).

• Glucose monitoring before dosing: The label directs pre-meal glucose checks from initiation until a dose is tolerated, and continued checks if symptoms recur (INCRELEX prescribing information); the manufacturer’s registry defines documented hypoglycaemia as below 50 mg/dL (NCT00903110).

• Cancer history before any exposure: A documented personal and family cancer history identifies those in whom the mitogenic concern concentrates; the source does not support intensive screening on exposure alone (Dominikowski et al., 2026).

• Baseline and periodic eye examination: Funduscopic examination at initiation and periodically is the labelled mitigation for raised intracranial pressure, and it also captures retinopathy progression (INCRELEX prescribing information).

• No stacking with other axis agents: Combining with growth hormone, secretagogues or anabolic steroids multiplies oedema, dysglycaemia (unstable blood sugar) and mitogenic exposure and makes any adverse event unattributable (Dominikowski et al., 2026).

• Injection-site rotation: Site rotation at every injection is the labelled measure against lipohypertrophy (INCRELEX prescribing information), which affected 32% of children on long-term native hormone (Chernausek et al., 2007).

• Escalation on red-flag symptoms: Severe headache with visual change, marked hyperglycaemia (high blood sugar), breathlessness with rapid fluid gain, or spreading injection-site inflammation are red flags warranting a low threshold for urgent medical escalation (Dominikowski et al., 2026).

Therapeutic Protocol

No regulated protocol exists for IGF-1 LR3 in humans: it has never been through a human trial, carries no approved label, and no clinical guideline or named clinic has published a regimen for it. Parameters without a citation below (timing, cycling, titration) reflect common practice for the drug class rather than evidence for this compound.

• Only sourced dosing reference: The approved native-hormone product is given subcutaneously twice daily, starting at 0.04–0.08 mg/kg and rising by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg, for severe primary IGF-1 deficiency in children (INCRELEX prescribing information).

• Why that reference does not transfer: Different molecule, paediatric growth indication, deficiency state. Adults with normal IGF-1 have no target to titrate toward, and a year-long randomised trial in healthy older women showed nothing (Friedlander et al., 2001).

• What circulates instead: The one clinical review covering this compound tabulates a forum regimen — 20–40 µg daily, subcutaneous or intramuscular, post-workout, 4–6 weeks on, equal time off — and states it is not validated or safe (Dominikowski et al., 2026).

• Competing approaches: For the same goals, resistance training with adequate protein, supervised growth-hormone replacement where deficiency is documented, and the approved native hormone within its licensed indication are the alternatives; none has been compared against this analogue.

• Best time of day: The only sourced timing rule is food-anchored, not clock-anchored: the approved native hormone is given within 20 minutes either side of a meal to limit hypoglycaemia (INCRELEX prescribing information).

• Half-life: No human half-life has been published for this analogue. In rats it is cleared about tenfold faster than native IGF-1 (Bastian et al., 1993); the approved native hormone’s half-life after subcutaneous dosing is 5.8 hours (INCRELEX prescribing information).

• Single versus split dosing: The approved native-hormone precedent is twice-daily dosing because of the short measured half-life (INCRELEX prescribing information). Claims of once-daily sufficiency rest on an unsourced 20–30 hour figure.

• Genetic polymorphisms: No pharmacogenetic data exist. A growth-hormone receptor variant missing one gene segment and IGF1 on-switch-region variants are plausible dose modifiers by pathway logic only, and no protocol adjusts for them (theoretical).

• Sex-based differences: No sex-specific dosing data exist for this compound. Mouse and human longevity data show larger effects of reduced IGF-1 signalling in females (Holzenberger et al., 2003; Milman et al., 2014), arguing against symmetrical use.

• Age-related considerations: Adults have closed growth plates, a labelled contraindication for growth promotion (INCRELEX prescribing information), and pooled cohorts place the lowest mortality mid-range, not high (Rahmani et al., 2022).

• Baseline biomarkers: Where any protocol logic exists, it anchors on pre-treatment IGF-1 and glucose handling; people already mid-range on IGF-1 have no deficit to correct (Rahmani et al., 2022).

• Pre-existing conditions: Diabetes, retinopathy, prior malignancy and impaired kidney function each change the calculus, the last because the analogue concentrates in kidney tissue in animals (Bastian et al., 1993).

Discontinuation & Cycling

• Lifelong versus short-term: No human use pattern is established. The approved native hormone is used until growth is complete, a logic with no adult equivalent (INCRELEX prescribing information).

• Withdrawal effects: None documented in humans. Animal infusions lowered the body’s own IGF-1, IGF-2 and binding proteins (Conlon et al., 1995), so a transient post-stop trough is biologically plausible but unmeasured.

• Tapering: No taper protocol exists. Clearance has been measured only in rats, where it is fast (Bastian et al., 1993); whether stopping abruptly leaves any lingering drug effect in humans is unmeasured.

• Cycling for efficacy: Multi-week on-off cycling appears only in grey-literature protocols, with no efficacy or safety rationale from any study (Dominikowski et al., 2026).

• Stopping on a finding: Discontinuation is the labelled response to evidence of malignancy, and dose interruption the response to raised intracranial pressure (INCRELEX prescribing information).

Sourcing and Quality

• No pharmaceutical-grade human product exists: FDA notes that IGF-1 LR3 is not a component of any approved drug (FDA warning letter, 2020). Material on the market is produced for research or cell culture, and the commercial cell-culture grade is explicitly designated non-therapeutic.

• Compounding is not a legal route: FDA states that products compounded with IGF1-LR3 fall outside section 503A exemptions: no applicable monograph, not part of an approved drug, not on the 503A bulks list (FDA warning letter, 2020).

• Identity cannot be assumed: Doping chemists found a confiscated vial contained a histidine-tagged variant made for biochemistry, not injection, whose human effects are undescribed (Kohler et al., 2010).

• Third-party testing does not resolve this: Products sold as research chemicals carry uncertain purity, dose consistency and sterility, and sterility cannot be assumed in informal distribution channels — the attributes that drive injection risk (Dominikowski et al., 2026).

• Reputable sources: None can be named for human use. The only regulated IGF-1 products are the approved native-hormone injections dispensed by prescription for their licensed indication (INCRELEX prescribing information).

• Formulation and handling: Research-grade freeze-dried powder carries no stability or preservative data for human use; the approved comparator is a preserved liquid whose benzyl-alcohol content itself carries a labelled infant warning (INCRELEX prescribing information).

Practical Considerations

• Regulatory status: Not approved for any indication, not eligible for pharmacy compounding (FDA warning letter, 2020), and prohibited at all times in sport as an IGF-1 analogue under category S2.3 (WADA Prohibited List).

• Time to effect: Unknown in humans, since no human endpoint has been measured. In rats, gut tissue enlarged within 7–14 days of continuous infusion (Lemmey et al., 1994; Steeb et al., 1994); no human time course exists.

• Common pitfall — assuming a long half-life: The circulating 20–30 hour figure has no peer-reviewed source, and measured clearance of this analogue is faster than native IGF-1 (Bastian et al., 1993).

• Common pitfall — reading animal potency as human benefit: The analogue’s edge over native IGF-1 appears only where carrier proteins are present and plentiful; it is weaker than native IGF-1 at the receptor itself (Francis et al., 1992).

• Common pitfall — self-attributing symptoms to one peptide: Real-world use is usually alongside other agents, which makes any symptom cluster unattributable without a full exposure history (Dominikowski et al., 2026).

• No payer influence on the evidence: The cheap research-grade compound and the costly licensed hormone are not reimbursement alternatives — no insurer or health system covers either for this purpose, so no institutional payer incentive shapes the evidence base or any guideline here.

• Cost and accessibility: Research-grade vials are inexpensive relative to prescription hormones, which is itself a hazard: low cost comes from an unregulated supply chain with no sterility or identity assurance (Kohler et al., 2010).

Interaction with Foundational Habits

• Sleep: Indirect and bidirectional. Growth hormone is released mainly in slow-wave (deep) sleep and drives the body’s own IGF-1, so poor sleep lowers the baseline being targeted; exogenous IGF-1 feeds back to suppress pituitary output. Sleep apnoea is a labelled targeted event, worsened by tonsillar overgrowth (Bang et al., 2021).

• Nutrition: Direct and non-optional. The insulin-like effect anchors dosing to a meal: the label specifies administration within 20 minutes either side, withholding the dose if no meal follows (INCRELEX prescribing information). High protein and dairy intake track higher endogenous IGF-1 (Rahmani et al., 2022).

• Exercise: Potentiating in theory, unmeasured in fact. Grey-literature protocols time doses post-workout, though no study has tested whether this analogue changes a training response (Dominikowski et al., 2026). The native hormone’s label lists exercise among the high-risk activities to avoid in the 2–3 hours after a dose, because of hypoglycaemia (INCRELEX prescribing information).

• Stress management: Blunting. Cortisol and corticosteroid exposure oppose IGF-1 action and raise binding-protein concentrations, and in steroid-treated rats the analogue partly reversed the resulting wasting (Tomas et al., 1992). Chronic stress therefore both worsens the catabolic state and dampens the response.

Monitoring Protocol & Defining Success

Before any exposure, the useful baseline is narrow and safety-oriented: an age-adjusted serum IGF-1 to establish where the person actually sits on the mortality curve, fasting glucose and glycated haemoglobin to characterise glucose handling, and a dilated funduscopic examination, which the approved native hormone’s label recommends at initiation (INCRELEX prescribing information). Age- and sex-appropriate cancer screening belongs here too, because active or prior malignancy is a labelled contraindication rather than a monitoring item. During use, the label sets pre-meal glucose checks from initiation until a dose is tolerated, then whenever symptoms recur, and periodic funduscopic examination; by common practice, IGF-1 and glycated haemoglobin are rechecked at roughly 4–6 weeks and then every 3–6 months. Success cannot be defined against an outcome for this compound, because none has been measured in humans — only absence of harm can be tracked.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum IGF-1	120–160 ng/mL, the band with lowest all-cause mortality in pooled cohorts (Rahmani et al. 2022)	Expected to change: tracks own IGF-1 suppression and mortality-curve position	Animal infusions lowered native IGF-1, and assays may not detect the analogue. The conventional reference range is age-, sex- and assay-specific and falls continuously through adult life (Bidlingmaier et al., 2014): about 75–216 ng/mL in men and 62–204 ng/mL in women aged 41–45, and 49–188 and 42–169 ng/mL at 61–65 (standard reference range; Mayo Clinic Laboratories IGF-1 reference values); the approved native hormone’s label uses standard deviation scores (distance from the age-and-sex average) rather than a fixed interval (INCRELEX prescribing information). Interpret cautiously during inflammation or malnutrition, which lower IGF-1 (Rahmani et al., 2022)
Fasting plasma glucose	70–99 mg/dL (standard reference range)	Safety check: detects hypoglycaemia, the acute dose-limiting event	Below 50 mg/dL is the manufacturer registry’s documented-hypoglycaemia threshold. 8-hour fast; pre-meal capillary testing is the label’s monitoring method at initiation, and continuous glucose monitoring gives the same information with fewer gaps (INCRELEX prescribing information); threshold from the registry protocol (NCT00903110)
Glycated haemoglobin (HbA1c)	4.0–5.6% (standard reference range)	Expected to change: integrated glucose control over about three months	Fell on the native hormone in diabetes. No fasting needed; unreliable in anaemia, recent transfusion or haemoglobin variants. Pair with fasting glucose (Thrailkill et al., 1999)

Qualitative markers worth tracking alongside the labs:

• Symptoms of low blood sugar — shakiness, sweating, confusion, early-morning headache — especially in the hours after a dose
• Morning facial or hand puffiness, ring tightness and new joint or jaw discomfort, the signature of fluid retention
• Headache with nausea, vomiting or visual change, which is the escalation trigger for raised intracranial pressure
• Snoring, witnessed apnoea or a change in swallowing, pointing to lymphoid overgrowth
• Injection-site appearance: thickening, nodules, redness or persistent soreness

Emerging Research

• No trial of this compound is registered: A ClinicalTrials.gov search returns no interventional study of IGF-1 LR3 in any condition. A positive first-in-human pharmacokinetic study would move the compound out of the no-human-data tier; continued absence keeps every claim about it extrapolated (Dominikowski et al., 2026).

• Increlex global safety registry: An open-ended manufacturer-sponsored surveillance registry of up to 500 children on native rhIGF-1, tracking neoplasia (new tumour growth), hypoglycaemia and intracranial hypertension, with primary completion December 2027 (NCT00903110). Excess neoplasia would strengthen the mitogenic risk item; a null signal would weaken it.

• IGF-1 in ageing skin: Early-phase study injecting IGF-1 into geriatric skin before ultraviolet exposure, 24 participants, measuring DNA-protective gene expression (NCT03932162). Listed as recruiting, completion December 2025; results submitted July 2026, not yet posted. A positive result would add a Speculative skin-repair item; a null result would leave the conclusion unchanged.

• Where the mortality question goes next: Pooled cohorts place lowest mortality mid-range and show harm at both extremes (Rahmani et al., 2022; Burgers et al., 2011). Genetic studies partly support a causal cancer link (Larsson et al., 2020; Murphy et al., 2020); similar work on mortality would settle whether raising IGF-1 is harmful.

• Evidence that could weaken the case further: Low IGF-1 predicted longer survival in exceptionally long-lived women (Milman et al., 2014), and reduced receptor signalling extended mouse lifespan (Holzenberger et al., 2003). Replication in men would make deliberate pathway activation harder to defend on longevity grounds.

• Evidence that could strengthen it: After the analogue failed to improve growth in growth-restricted fetal sheep, the authors speculated that limiting substrate may have blocked the effect (White et al., 2025). A co-supplementation study showing recovered effect would identify the conditions under which it does anything.

Conclusion

IGF-1 LR3 is a laboratory-built version of a natural growth signal, reshaped so that blood carrier proteins cannot capture it. That design change is its whole appeal, made to answer a research question, not to treat anybody. Thirty-four years later, the central fact about this molecule is still that no study has given it to a human being and measured what happened.

Instead there are two bodies of evidence, each a step removed. Animal and cell work shows it doing more than the natural hormone in tissue growth, blood-sugar lowering and gut repair — and, in one kidney-injury model, worsening kidney function. Human work uses the natural hormone or an approved version of it, where benefits clustered in people whose own signalling was impaired and vanished in healthy older adults, while swelling, jaw pain, low blood sugar, tissue overgrowth and eye changes were documented.

Set against that thinness is a consistent population finding: both unusually low and unusually high levels of this signal track higher death rates, with the lowest risk in the middle, and higher levels track more of several common cancers. Most animal evidence for this molecule comes from the group that developed it and sold it for cell culture, and much of the human safety data comes from the native hormone’s manufacturer, through its own registry and label. For an adult already in the middle of that range, the evidence describes a deliberate push away from it, with no human measurement of where it lands.

Top - Benefits - Risks - Protocol